Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6-Reference-Cited by-同舟云学术

Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

Published:2005-03-02 Issue:7 Volume:48 Page:2388-2406
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Toogood Peter L.¹,Harvey Patricia J.¹,Repine Joseph T.¹,Sheehan Derek J.¹,VanderWel Scott N.¹,Zhou Hairong¹,Keller Paul R.¹,McNamara Dennis J.¹,Sherry Debra¹,Zhu Tong¹,Brodfuehrer Joanne¹,Choi Chung¹,Barvian Mark R.¹,Fry David W.¹

Affiliation:

1. Medicinal Chemistry, Cancer Pharmacology, and Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm049354h

Reference96 articles.

1. Small Molecules as Inhibitors of Cyclin-Dependent Kinases

2. The RB and p53 pathways in cancer

3. Novel drugs targeting the cell cycle

Cited by 431 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Exploring Natural Compounds as Potential CDK4 Inhibitors for Therapeutic Intervention in Neurodegenerative Diseases through Computational Analysis;Molecular Biotechnology;2024-08-29

3. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

4. Post-GWAS Validation of Target Genes Associated with HbF and HbA2 Levels;Cells;2024-07-12

5. Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy;Cancer Imaging;2024-07-09